Ovid Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated March 17, 2026, details a material definitive agreement entered into by Ovid Therapeutics Inc. The filing covers a private placement financing transaction (PIPE) and references a press release issued on March 18, 2026, regarding clinical data and financial results for the fourth quarter and full year 2025.
Key Financial Metrics and Transaction Details
- Financing Structure: The Company agreed to sell 19,154,321 shares of Common Stock at $2.01 per share and pre-funded warrants for up to 10,701,710 shares at $2.009 per warrant.
- Gross Proceeds: The PIPE financing is expected to generate approximately $60.0 million in gross proceeds before fees and expenses.
- Use of Proceeds: Funds will support the expansion of OV329 (a next-generation GABA-AT inhibitor) into tuberous sclerosis complex and infantile spasms, alongside general R&D expenses.
- Closing Date: Expected on or about March 19, 2026.
- Financial Results: The filing references Q4 and full-year 2025 results in an attached press release but does not provide specific revenue, profit, or cash flow figures within the text of this 8-K.
Material Changes and Agreements
The primary material change is the entry into a Securities Purchase Agreement and a Registration Rights Agreement. The Registration Rights Agreement obligates the Company to file a registration statement for the resale of securities within 30 business days of closing and use reasonable best efforts to have it declared effective within 60 days thereafter. The Company will bear all registration fees and expenses.
Outlook, Risks, and Management Commentary
Management intends to utilize the new capital to advance the development of OV329 into additional indications. The filing notes that the securities were sold in reliance on Section 4(a)(2) of the Securities Act and are not registered. The closing is subject to customary conditions. Specific risks, contingencies, or unusual items beyond the standard closing conditions and registration obligations are not detailed in this summary text.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $60.0 million gross proceeds.
- Review the attached press release (Exhibit 99.1) for specific Q4 and full-year 2025 financial metrics (revenue, cash burn, net loss) which are not included in this 8-K text.
- Confirm the dilution impact of the 19,154,321 shares and 10,701,710 pre-funded warrants on existing shareholders.
- Monitor the filing of the registration statement for the resale of securities within the required 30-business-day window post-closing.